ReP USP - Resultado da busca

Artigo de periodico
High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial (2017)
Eisen, Alon; Bonaca, Marc P.; Scirica, Benjamin M.; White, Harvey D.; Tendera, Michal; Dellborg, Mikael; Nicolau, Jose C.; Morais, Joao; Fox, Keith A. A.; Bohula, Erin A.; Murphy, Sabina A.; Braunwald, Eugene; Morrow, David A.
Fonte: Clinical Chemistry. Unidade: FM
Assuntos: BIOMARCADOR, TROPONINA, DOENÇAS CARDIOVASCULARES, ARTERIOSCLEROSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EISEN, Alon et al. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, v. 63, n. 1, p. 307-315, 2017Tradução . . Disponível em: https://doi.org/10.1373/clinchem.2016.264788. Acesso em: 06 out. 2024.
APA
Eisen, A., Bonaca, M. P., Scirica, B. M., White, H. D., Tendera, M., Dellborg, M., et al. (2017). High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, 63( 1), 307-315. doi:10.1373/clinchem.2016.264788
NLM
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 out. 06 ] Available from: https://doi.org/10.1373/clinchem.2016.264788
Vancouver
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 out. 06 ] Available from: https://doi.org/10.1373/clinchem.2016.264788
Artigo de periodico
Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial (2016)
Lopes, Renato D.; Leonardi, Sergio; Neely, Benjamin; Neely, Megan L.; Ohman, E. Magnus; Ardissino, Diego; Hamm, Christian W.; Goodman, Shaun G.; Bhatt, Deepak L.; White, Harvey D.; Prabhakaran, Dorairaj; Martinez, Felipe; Nicolau, Jose C.; Winters, Kenneth J.; Fox, Keith A. A.; Armstrong, Paul W.; Roe, Matthew T.
Fonte: Journal of the American College of Cardiology. Unidade: FM
Assuntos: INFARTO DO MIOCÁRDIO, FÁRMACOS (SISTEMA CARDIOVASCULAR), ESTUDOS RANDOMIZADOS, REVASCULARIZAÇÃO MIOCÁRDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LOPES, Renato D. et al. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Journal of the American College of Cardiology, v. 67, n. 11, p. 1289-1297, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2016.01.034. Acesso em: 06 out. 2024.
APA
Lopes, R. D., Leonardi, S., Neely, B., Neely, M. L., Ohman, E. M., Ardissino, D., et al. (2016). Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Journal of the American College of Cardiology, 67( 11), 1289-1297. doi:10.1016/j.jacc.2016.01.034
NLM
Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KAA, Armstrong PW, Roe MT. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 11): 1289-1297.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/j.jacc.2016.01.034
Vancouver
Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KAA, Armstrong PW, Roe MT. Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial [Internet]. Journal of the American College of Cardiology. 2016 ; 67( 11): 1289-1297.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/j.jacc.2016.01.034
Artigo de periodico
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States (2015)
Magnani, Giulia; Bonaca, Marc P.; Braunwald, Eugene; Dalby, Anthony J.; Fox, Keith A. A.; Murphy, Sabina A.; Nicolau, José Carlos; Ophuis, Ton Oude; Scirica, Benjamin M.; Spinar, Jindrich; Theroux, Pierre; Morrow, David A.
Fonte: Journal of the American Heart Association. Unidade: FM
Assuntos: INFARTO DO MIOCÁRDIO (PREVENÇÃO E CONTROLE), FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, PLAQUETAS SANGUÍNEAS (ANORMALIDADES), ARTERIOSCLEROSE (TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAGNANI, Giulia et al. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, v. 4, n. art., p. 9 2015, 2015Tradução . . Disponível em: https://doi.org/10.1161/JAHA.114.001505. Acesso em: 06 out. 2024.
APA
Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., et al. (2015). Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, 4( art.), 9 2015. doi:10.1161/JAHA.114.001505
NLM
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Ophuis TO, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States [Internet]. Journal of the American Heart Association. 2015 ; 4( art.): 9 2015.[citado 2024 out. 06 ] Available from: https://doi.org/10.1161/JAHA.114.001505
Vancouver
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Ophuis TO, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States [Internet]. Journal of the American Heart Association. 2015 ; 4( art.): 9 2015.[citado 2024 out. 06 ] Available from: https://doi.org/10.1161/JAHA.114.001505
Artigo de periodico
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial (2015)
Nicolau, Jose Carlos; Bhatt, Deepak L.; Roe, Matthew T.; Lokhnygina, Yuliya; Neely, Benjamin; Corbalán, Ramón; Leiva-Pons, José L.; Martinez, Felipe; Goodman, Shaun G.; Winters, Kenneth J.; Verheugt, Freek W.A.; Armstrong, Paul W.; White, Harvey D.; Fox, Keith A. A.; Prabhakaran, Dorairaj; Ohman, E. Magnus
Fonte: American Heart Journal. Unidade: FM
Assuntos: SÍNDROME CORONARIANA AGUDA, MEDICAMENTO (ADMINISTRAÇÃO E DOSAGEM), ADMINISTRAÇÃO DOS CUIDADOS AO PACIENTE, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, Jose Carlos et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, v. 170, n. 4, p. 683-694, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2015.05.017. Acesso em: 06 out. 2024.
APA
Nicolau, J. C., Bhatt, D. L., Roe, M. T., Lokhnygina, Y., Neely, B., Corbalán, R., et al. (2015). Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, 170( 4), 683-694. doi:10.1016/j.ahj.2015.05.017
NLM
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Vancouver
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Artigo de periodico
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial (2013)
Wiviott, Stephen D.; White, Harvey D.; Ohman, E. Magnus; Fox, Keith A. A.; Armstrong, Paul W.; Prabhakaran, Dorairaj; Hafley, Gail Yuliya Lokhnygina; Lokhnygina, Yuliya; Boden, William E.; Hamm, Christian; Clemmensen, Peter; Nicolau, Jose C.; Menozzi, Alberto; Ruzyllo, Witold; Widimsky, Petr; Oto, Ali; Leiva-Pons, Jose; Pavlides, Gregory; Winters, Kenneth J.; Roe, Matthew T.; Bhatt, Deepak L.
Fonte: Lancet. Unidade: FM
Assuntos: ANGINA INSTÁVEL, INFARTO DO MIOCÁRDIO, ANGIOGRAFIA, CORONORAIOPATIA, DOENÇAS CARDIOVASCULARES (MORTALIDADE), REVASCULARIZAÇÃO MIOCÁRDICA (COMPLICAÇÕES)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WIVIOTT, Stephen D. et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, v. 382, n. 9892, p. 605-613, 2013Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(13)61451-8. Acesso em: 06 out. 2024.
APA
Wiviott, S. D., White, H. D., Ohman, E. M., Fox, K. A. A., Armstrong, P. W., Prabhakaran, D., et al. (2013). Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, 382( 9892), 605-613. doi:10.1016/S0140-6736(13)61451-8
NLM
Wiviott SD, White HD, Ohman EM, Fox KAA, Armstrong PW, Prabhakaran D, Hafley GYL, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial [Internet]. Lancet. 2013 ; 382( 9892): 605-613.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(13)61451-8
Vancouver
Wiviott SD, White HD, Ohman EM, Fox KAA, Armstrong PW, Prabhakaran D, Hafley GYL, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial [Internet]. Lancet. 2013 ; 382( 9892): 605-613.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(13)61451-8
Artigo de periodico
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial (2010)
Mehta, Shamir R.; Tanguay, Jean-François; Eikelboom, John W.; Jolly, Sanjit; Joyner, Campbell D.; Granger, Christopher B.; Faxon, David; Rupprecht, Hans Jurgen; Budaj, Andrzej; Avezum, Alvaro; Widimsky, Petr; Steg, Phillipe Gabriel; Bassand, Jean Pierre; Montalescot, Gilles; Macaya, Carlos; Pasquale, Giuseppe Di; Niemela, Kari; Ajani, Andrew E.; White, Harvey D.; Cholavicius, Susan; Gao, Peggy; Fox, Keith A. A.; Yusuf, Salim; Marin Neto, José Antonio
Fonte: The Lancet. Unidade: FMRP
Assuntos: FÁRMACOS, CARDIOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEHTA, Shamir R. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet, v. 376, n. 9748, p. 1233-1243, 2010Tradução . . Disponível em: https://doi.org/10.1016/s0140-6736(10)61088-4. Acesso em: 06 out. 2024.
APA
Mehta, S. R., Tanguay, J. -F., Eikelboom, J. W., Jolly, S., Joyner, C. D., Granger, C. B., et al. (2010). Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet, 376( 9748), 1233-1243. doi:10.1016/s0140-6736(10)61088-4
NLM
Mehta SR, Tanguay J-F, Eikelboom JW, Jolly S, Joyner CD, Granger CB, Faxon D, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Pasquale GD, Niemela K, Ajani AE, White HD, Cholavicius S, Gao P, Fox KAA, Yusuf S, Marin Neto JA. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial [Internet]. The Lancet. 2010 ; 376( 9748): 1233-1243.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/s0140-6736(10)61088-4
Vancouver
Mehta SR, Tanguay J-F, Eikelboom JW, Jolly S, Joyner CD, Granger CB, Faxon D, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Pasquale GD, Niemela K, Ajani AE, White HD, Cholavicius S, Gao P, Fox KAA, Yusuf S, Marin Neto JA. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial [Internet]. The Lancet. 2010 ; 376( 9748): 1233-1243.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/s0140-6736(10)61088-4
Artigo de periodico
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes (2010)
Bassand, Jean-Pierre; Chrolavicius, Susan; Diaz, Rafael; Eikelboom, John W.; Fox, Keith A. A.; Granger, Christopher B.; Jolly, Sanjit; Marin Neto, Jose Antonio
Fonte: The New England Journal of Medicine. Unidade: FMRP
Assuntos: FÁRMACOS, CARDIOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BASSAND, Jean-Pierre et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England Journal of Medicine, v. 363, n. 10, p. 930-942, 2010Tradução . . Acesso em: 06 out. 2024.
APA
Bassand, J. -P., Chrolavicius, S., Diaz, R., Eikelboom, J. W., Fox, K. A. A., Granger, C. B., et al. (2010). Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England Journal of Medicine, 363( 10), 930-942.
NLM
Bassand J-P, Chrolavicius S, Diaz R, Eikelboom JW, Fox KAA, Granger CB, Jolly S, Marin Neto JA. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England Journal of Medicine. 2010 ; 363( 10): 930-942.[citado 2024 out. 06 ]
Vancouver
Bassand J-P, Chrolavicius S, Diaz R, Eikelboom JW, Fox KAA, Granger CB, Jolly S, Marin Neto JA. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England Journal of Medicine. 2010 ; 363( 10): 930-942.[citado 2024 out. 06 ]
Artigo de periodico
Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events (2010)
Ambrosio, Giuseppe; Del Pinto, Maurizio; Tritto, Isabella; Agnelli, Giancarlo; Bentivoglio, Maurizio; Zuchi, Cinzia; Anderson, Frederick A.; Gore, Joel M.; López-Sendón, Jose; Wyman, Allison; Kennelly, Brian M.; Fox, Keith A. A.; Marin Neto, Jose Antonio; Pazin Filho, Antonio
Fonte: European Heart Journal. Unidade: FMRP
Assuntos: ISQUEMIA MIOCÁRDICA, NITRATOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AMBROSIO, Giuseppe et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events. European Heart Journal, v. 31, n. 4, p. 430-438, 2010Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehp457. Acesso em: 06 out. 2024.
APA
Ambrosio, G., Del Pinto, M., Tritto, I., Agnelli, G., Bentivoglio, M., Zuchi, C., et al. (2010). Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events. European Heart Journal, 31( 4), 430-438. doi:10.1093/eurheartj/ehp457
NLM
Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, Anderson FA, Gore JM, López-Sendón J, Wyman A, Kennelly BM, Fox KAA, Marin Neto JA, Pazin Filho A. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events [Internet]. European Heart Journal. 2010 ; 31( 4): 430-438.[citado 2024 out. 06 ] Available from: https://doi.org/10.1093/eurheartj/ehp457
Vancouver
Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, Anderson FA, Gore JM, López-Sendón J, Wyman A, Kennelly BM, Fox KAA, Marin Neto JA, Pazin Filho A. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52 693 patients in the Global Registry of Acute Coronary Events [Internet]. European Heart Journal. 2010 ; 31( 4): 430-438.[citado 2024 out. 06 ] Available from: https://doi.org/10.1093/eurheartj/ehp457
Artigo de periodico
The expanded global registry of acute coronary events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes (2009)
Goodman, Shaun G.; Huang, Wel; Yan, Andrew T.; Budaj, Andrej; Kennelly, Brian M.; Gore, Joel M.; Fox, Keith A. A.; Goldberg, Robert J.; Anderson, Frederick A.; Marin Neto, José Antonio; Pazin Filho, Antonio
Fonte: American Heart Journal. Unidade: FMRP
Assuntos: CORONARIOPATIA (TRATAMENTO), MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOODMAN, Shaun G. et al. The expanded global registry of acute coronary events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. American Heart Journal, v. 158, n. 2, p. 193-201.e5, 2009Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2009.06.003. Acesso em: 06 out. 2024.
APA
Goodman, S. G., Huang, W., Yan, A. T., Budaj, A., Kennelly, B. M., Gore, J. M., et al. (2009). The expanded global registry of acute coronary events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. American Heart Journal, 158( 2), 193-201.e5. doi:10.1016/j.ahj.2009.06.003
NLM
Goodman SG, Huang W, Yan AT, Budaj A, Kennelly BM, Gore JM, Fox KAA, Goldberg RJ, Anderson FA, Marin Neto JA, Pazin Filho A. The expanded global registry of acute coronary events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes [Internet]. American Heart Journal. 2009 ; 158( 2): 193-201.e5.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/j.ahj.2009.06.003
Vancouver
Goodman SG, Huang W, Yan AT, Budaj A, Kennelly BM, Gore JM, Fox KAA, Goldberg RJ, Anderson FA, Marin Neto JA, Pazin Filho A. The expanded global registry of acute coronary events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes [Internet]. American Heart Journal. 2009 ; 158( 2): 193-201.e5.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/j.ahj.2009.06.003
Artigo de periodico
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction (2006)
Antman, Elliott M.; Morrow, David A.; McCabe, Carolyn H.; Murphy, Sabina A.; Ruda, Mikhail; Sadowsky, Zygmunt; Budaj, Andrzej; López-Sendón, Jose L.; Guneri, Sema; Jiang, Frank; White, Harvey D.; Fox, Keith A. A.; Braunwald, Eugene; Marin-Neto, José Antônio
Fonte: The New England Journal of Medicine. Unidade: FMRP
Assuntos: INFARTO DO MIOCÁRDIO, FIBRINÓLISE, ANTICOAGULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANTMAN, Elliott M. et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England Journal of Medicine, v. 354, p. 1477-1488, 2006Tradução . . Acesso em: 06 out. 2024.
APA
Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowsky, Z., et al. (2006). Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England Journal of Medicine, 354, 1477-1488.
NLM
Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowsky Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KAA, Braunwald E, Marin-Neto JA. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England Journal of Medicine. 2006 ; 354 1477-1488.[citado 2024 out. 06 ]
Vancouver
Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowsky Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KAA, Braunwald E, Marin-Neto JA. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England Journal of Medicine. 2006 ; 354 1477-1488.[citado 2024 out. 06 ]
Artigo de periodico
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial (2004)
Lemos, James A.; Blazing, Michael A.; Wiviott, Stephen D.; Lewis, Eldrin F.; Fox, Keith A. A.; White, Harvey D.; Rouleau, Jean-Lucien; Pedersen, Terje; Gardner, Laura H.; Mukherjee, Robin; Ramsey, Karen E.; Palmisano, Joanne; Bilheimer, David W.; Pfeffer, Marc A.; Califf, Robert M.; Braunwald, Eugene; Marin-Neto, José Antônio
Fonte: JAMA. Unidade: FMRP
Assunto: CORONARIOPATIA (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEMOS, James A. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA, v. 292, n. 11, p. 1307-1316, 2004Tradução . . Acesso em: 06 out. 2024.
APA
Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., et al. (2004). Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA, 292( 11), 1307-1316.
NLM
Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen T, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Marin-Neto JA. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004 ; 292( 11): 1307-1316.[citado 2024 out. 06 ]
Vancouver
Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen T, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Marin-Neto JA. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA. 2004 ; 292( 11): 1307-1316.[citado 2024 out. 06 ]
Artigo de periodico
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial (2004)
Blazing, Michael A.; Lemos, James A. de; White, Harvey; Fox, Keith A. A.; Verheugt, Freek W. A.; Ardissino, Diego; DiBattiste, Peter M.; Palmisano, Joanne; Bilheimer, David W.; Snapinn, Steven M.; Ramsey, Karen E.; Gardner, Laura H.; Hasselblad, Vic; Pfeffer, Marc A.; Lewis, Eldrin F.; Braunwald, Eugene; Califf, Robert M.; Marin-Neto, José Antônio
Fonte: JAMA. Unidade: FMRP
Assuntos: INFARTO DO MIOCÁRDIO (TRATAMENTO), ISQUEMIA MIOCÁRDICA (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BLAZING, Michael A. et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA, 2004Tradução . . Acesso em: 06 out. 2024.
APA
Blazing, M. A., Lemos, J. A. de, White, H., Fox, K. A. A., Verheugt, F. W. A., Ardissino, D., et al. (2004). Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA.
NLM
Blazing MA, Lemos JA de, White H, Fox KAA, Verheugt FWA, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, Marin-Neto JA. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA. 2004 ;[citado 2024 out. 06 ]
Vancouver
Blazing MA, Lemos JA de, White H, Fox KAA, Verheugt FWA, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM, Marin-Neto JA. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA. 2004 ;[citado 2024 out. 06 ]

Unidades USP

ReP

Filtros

Autores

Ano de publicação

Assuntos

Título da fonte

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos